142 results about "Booster immunizations" patented technology

The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein. The enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.

The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.

The present invention belong to veterinary new biological medicine technology field, relates to porcine circovirus type II (PCV2) inactivated vaccine of and method for preparing same. The vaccine used seed virus is porcine circovirus type II DBN-SX07 strain, the preservation number is CGMCC No 3064, the virus strain is used as antigen preparation of inactivation by alkyl agents and emulsification by adding oil adjuvant. Using the invention provided PCV2 inactivated vaccine to immune pig can generate an uniform and effective protection force-shorting PCV2 infection windows period obviously, and prolong immune duration-reducing times of booster immunization.

A yolk antibody for SARS coronavirus is prepared through injecting the antigen, which may be recombinant genetic protein S, M, or E,or the antigen epitope for said protein able to represent SARS coronavirus, or the synthetic polypeptide of said protein, etc, in health hen for primary immunizing, booster immunizing, collecting its egg, extracting yolk, and extracting the yolk antibody from it. It can also be prepared to become liquid preparation. It can be used to prevent SARS.

The invention relates to a hybridoma cell strain secreting thiamethoxacin monoclonal antibody and application thereof, belonging to the field of food safety immunodetection. The accession number of the hybridoma cell strain is CGMCC No. 14699. According to the invention, a complete Freund's adjuvant is used for primary immunization of a BALB/c mouse, then an incomplete Freund's adjuvant is used for booster immunization three times, and a thiamethoxam complete antigen containing no adjuvant is used for impact immunization once, so the BALB/c mouse is immunized; and then the high-titer low-IC50spleen cells of the immunized mouse are fused with mouse myeloma cells by using a PEG method, and then the cell strain is obtained through indirect competitive ELISA screening and subcloning three times. The monoclonal antibody secreted by the cell strain has good specificity and detection sensitivity (with an IC50 value of 0.81 ng/mL) to thiamethoxam and can be used for detection of thiamethoxamresidues in food.

The present invention relates to immunogenic compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more excipients. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one excipient which acts as an adjuvant, i.e., enhances the immune response to the antigenic or immunogenic agent, once delivered to the intradermal compartment of a subject's skin. The immunogenic compositions of the invention comprise an excipient which when administered to the intradermal compartment of skin in accordance with the invention demonstrate adjuvant activity. The immunogenic compositions of the invention have enhanced efficacy as the excipients of the composition cause an asymptomatic skin irritation and recruit antigen presenting cells to the intradermal compartment and thus enhance presentation and/or availability of the antigenic or immunogenic agent to the antigen presenting cells. The enhanced efficacy of the immunogenic compositions of the invention may result in a therapeutically effective immune response after a single intradermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations

The invention discloses a thiacloprid and acetamiprid monoclonal antibody hybridoma cell strain GW and application thereof, and belongs to the field of food security immunodetection. Thiacloprid and acetamiprid complete antigen of the strain is uniformly mixed with an equal amount of QuickAntibody-Mouse 5W adjuvant, and is injected to BALB/c mice through leg muscle. The dosage is 100mu g/mouse for the first time of immunization, the dosage is 50[mu]g/mouse for multiple times of intensified immunization, the immunization is implemented at an interval of 21 days, and thiacloprid and acetamiprid complete antigen (25[mu]g/mouse, without adjuvant) is adopted for immunization impact for the last time. Splenocyte of high-potency low IC50 mice is taken and fused with mouse myeloma cells by using a PEG method, indirect competitive inhibition enzyme-linked immunosorbent assay is adopted for screening, and three times of subcloning is implemented, so as to obtain the hybridoma cell strain. A monoclonal antibody secreted from the cell strain has relatively good specificity and detection sensitivity (the IC50 values are 0.1ng/mL and 0.4ng/mL respectively) for thiacloprid and acetamiprid, detection on the residual amounts of thiacloprid and acetamiprid in water, fruits and vegetables and cereals can be achieved, conditions are provided for immunodetection on thiacloprid and acetamiprid residues in food can be provided, and practical use values can be made.

The invention describes an adenovirus vector which carries a HIV structure gene of codon optimization and/or a HIV regulatory and auxiliary gene as well as a heterogenous promoter and a transcription terminator. When a first-booster immunization proposal is adopted by a single or combined plasmid vector vaccine, the vector-viral vaccine can be used for preventing HIV infection.

The invention discloses a pig foot-and-mouth disease virus O type and A type Fc polypeptide bivalent vaccine, as well as a preparation method and application thereof. The bivalent vaccine is preparedfrom effective components of pig foot-and-mouth disease virus A type Fc polypeptide and pig foot-and-mouth disease virus O type Fc polypeptide, wherein an amino acid sequence of the pig foot-and-mouthdisease virus A type Fc polypeptide is as shown in SEQ ID NO.3; an amino acid sequence of the pig foot-and-mouth disease virus O type Fc polypeptide is as shown in SEQ ID NO.5. Experimental results show that the bivalent vaccine can induce a body to produce a high-level neutralizing antibody against O type and A type foot-and-mouth disease viruses after being subjected to booster immunization, can protect immunized pigs against the attack of the O type and A type foot-and-mouth disease viruses, and realizes 5/5 protection (i.e. the protection rate is 100 percent). The pig foot-and-mouth disease virus O type and A type Fc polypeptide bivalent vaccine, as well as the preparation method and the application thereof provided by the invention provide a technical support and vaccine storage forguaranteeing healthy sustainable development of animal husbandry in China and realizing a mid-and-long-term prevention and control aim of foot-and-mouth disease countries.

The invention relates to a preparation method for obtaining blood used for preparing homologous antiserums and a spleen byproduct used for preparing transfer factors from the bodies of fur bearing animals such as foxes, raccoon dogs and minks; the furs of the foxes, the raccoon dogs and the minks are taken concentratedly in December and confirmed according to the fur-taking dates of different areas; healthy individuals are picked up 45 days before a predicated fur-taking date; the booster immunization of univalent vaccines or polyvalent vaccines of canine distemper, Canine parvovirus enteritis, adenovirus disease, corona virus laxness, parainfluenza, and pasteurellosis is carried out for 3 times by purified and condensed antigens on the foundation of carrying out immunization for once in summer; when the furs are taken, aseptic anticoagulation blood collection is carried out to a heart to improve the blood serum yield; and the spleens of the animals are collected for extracting specific or common transfer factors simultaneously. The blood can be conveniently prepared into the blood serums which resist communicable diseases, and the transfer factors can be extracted the spleen, thus providing guarantee for the healthy development of the breeding in the next year; the invention is used for curing the corresponding communicable diseases of the wild animals of the same species; and when a small amount of communicable disease cases appear in a breeding crowd, the corresponding pathogeny hyper-immune serums and transfer factors are mainly injected to a supposed healthy crowd after the pathogeny is confirmed so as to cure the affected animals in the early period of disease and control the spreading of the epidemic situations.

Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two Neospora antigens—Neospora cyclophilin (NcCyP) and NcSRS2. The ability of native NcCyP to upregulate mouse IFNγ was also confirmed in this study. Recombinant NcCyP or NcSRS2 were tested either alone or in combination and formulated with adjuvant ImmuMax-SR and CpG. Female BALB/c mice (n=15) of 10-12 weeks of age were immunized s.c. twice in a 2-week interval with vaccines containing either NcCyP alone, NcSRS2 alone, NcCyP plus NcSRS2, or non-recombinant bacterial antigen (NR) in 2 separate trials. All mice were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Brain and serum were collected and Nc-specific DNA sequence in brain tissue and antibodies in serum were analyzed by PCR or ELISA/Western blotting. Results showed that mice vaccinated with rNcCyP, rNcSRS2, or both rNcCyP and rNcSRS2 responded with high levels of NcCyP or NcSRS2 specific antibodies. Overall, mice received vaccines formulated with either rNcCyP or rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. The groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection, which was higher (p<0.05) than that of the non-vaccinated group but did not differ (p=0.06) from that of the mock-vaccinated group. The results of the present study indicate that NcCyP is a highly efficacious vaccine candidate which may be useful in protection against Neospora infection.

The invention discloses a method for preparing IgY for SARS, which belongs to a process for manufacturing anti-SARS biological pharmaceuticals. The process comprises the steps of making vaccinogen, preparing antibody, homogenating vitelline, diluting, low-temperature stewing, filtering, purifying, and pulverizing. The said antibody preparation process is disclosed in the invention. The process according to the invention can be applied in preparing anti-SARS medicament.

The invention discloses a preparation method of a monoclonal antibody to chloramphenicol (CAP). The method comprises the following steps of: (1) preparing an antigen of CAP-BSA by a diazotization method; (2) conducting lymph immunization to mice with the CAP-BSA antigen, leaving the antigen and a Freund's complete adjuvant to complete emulsification during the first time immunization, and during the second time and the third time immunization, leaving the antigen and a Freund's incomplete adjuvant to complete emulsification, and keeping an interval of 7 days between each time, and 3 days before fusion, carrying out direct antigen injection to the abdominal cavity to booster immunization; (3) measuring serum titers of the mice by an enzyme-linked immunosorbent assay (ELISA) method; (4) selecting a mouse with the highest serum titer, and taking a spleen cell and a myeloma cell for in vitro fusion; (5) culturing and screening a fusion cell in a selective medium, conducting positive cell detection and screening for cloning culture, further performing positive cell cloning and screening for positive cloning, expanding culture and cryopreservation; (6) injecting a cell strain undergoing expanded culture into the abdominal cavities of the mouse so as to produce a lot of ascites; (7) using a chromatographic column to purify the monoclonal antibody against chloramphenicol in the ascites. The prepared monoclonal antibody against CAP-BSA has the advantages of high sensitivity, strong specificity and good practicality.

The invention provides a preparation method and use of safe and environment-friendly enterotoxigenic Escherichia coli (ETEC) egg yolk antibody powder. The preparation method comprises: selecting a healthy commercial egg-laying chicken, immunizing the egg-laying chicken by using pig ETEC triple vaccine as an antigen and injecting through muscle according to a ratio of 0.5 to 2ml/feather, obtaining specific IgY, immunizing for 50 days for the first time, starting to collect eggs, and preparing Escherichia coli egg yolk antibody powder, wherein immunization is performed again every other 40 days for reinforcement, and high-titer IgY eggs can be obtained continuously. Fresh egg yolk pulp is quickly dewatered and dried in several seconds by a spray drying technique to form Escherichia coli egg yolk antibody powder, the spray drying temperature at an inlet is 120 to 155 DEG C, the spray drying temperature at an outlet is 60 to 80 DEG C, and the Escherichia coli egg yolk antibody powder is kept in a drying tower for 2 to 3 hours. The preparation method has the advantages that: the Escherichia coli egg yolk antibody powder can be used as a feed additive for various kinds of livestock and poultry and widely used in livestock and poultry production; and the Escherichia coli egg yolk antibody powder can improve the production performance of piglets in early weanling period, has obvious effects on prevention and treatment of diarrhea in piglets and overcomes the drawbacks of coarse egg yolk antibody.